Wolfe Research downgrades DHR

What happened: Wolfe Research downgraded Danaher Corporation (DHR) to 'Peer Perform' from 'Outperform' on June 1, without assigning a price target. HSBC previously cut its price target on DHR to $230 from $270 on June 3, maintaining a 'Buy' rating. DHR, a top high-conviction stock among hedge funds, recently paid a dividend with an annualized yield of 0.86%.

Market impact: The downgrades and price target cut by Wolfe Research and HSBC, respectively, could lead to a re-evaluation of DHR's growth prospects by investors. This may impact the healthcare sector, particularly stocks with high conviction and upside potential.

What to watch next: Danaher's Q2 2023 earnings report, scheduled for late July, will provide insights into the company's growth trajectory. Additionally, any changes in hedge fund positions or further analyst revisions on DHR could signal shifts in investor sentiment towards the stock.